BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies
Author:
Kaufmann Stefan H. E.
Publisher
Springer New York
Reference101 articles.
1. Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010;181:1407–17.
2. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009;106:13980–5.
3. Aguilo N, Gonzalo-Asensio J, Alvarez-Arguedas S, et al. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat Commun. 2017;8:16085.
4. All-Party Parliamentary Group on Global Tuberculosis. The price of a pandemic: counting the cost of MDR-TB. London. 2015.
http://www.appg-tb.org.uk/#!publications/cghg
5. Andersen P, Kaufmann SH. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014;4:pii: a018523.